Key facts
- Notable investors include Eurazeo.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Excelya
- ·The full record, as it builds
Funding rounds
No funding rounds for Excelya are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Excelya
Provider of clinical research services intended to support biotech, pharmaceutical, and medical-device organizations. The company offers full-service contract research organization (CRO), functional-service-provider resourcing, regulatory affairs, clinical operations, data management, medical writing, and quality-assurance services, thereby helping clients conduct efficient, compliant, and scientifically robust clinical trials.
- Sector
- Business Products and Services (B2B)
- HQ
- Paris, France
- Founded
- 2014
- Employees
- 800
- Website
- excelya.com/
- Ownership
- Privately Held (backing)
Excelya doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Excelya shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Excelya in its N-PORT filings yet. We sweep new filings monthly.